Polysubstance Use

What polysubstance use is and why it is so common

Polysubstance use is the use of two or more substances, whether intentionally in combination, sequentially to manage the effects of one another, or because one substance is contaminated with another. Common motivations include using a depressant to ease the crash of a stimulant, using a stimulant to counteract sedation from opioids or alcohol, combining substances to intensify or prolong a high, and self-medicating anxiety or insomnia with alcohol or sedatives while also using stimulants or opioids.

From a neurological standpoint, addiction across multiple substances develops because each one reinforces the cycle of use. The brain's reward, stress response, and inhibitory control systems adapt to multiple chemical signals simultaneously, producing a more complex and entrenched pattern of dependence than single-substance use alone. SAMHSA population surveys consistently find that the majority of people with a substance use disorder use more than one substance.

Fentanyl contamination has made polysubstance use more prevalent and more dangerous even for people who believe they are using only one drug. Someone who uses only cocaine may be unknowingly consuming fentanyl in a contaminated batch. This makes naloxone access and fentanyl test strips relevant across substance categories.

Common polysubstance patterns and their specific risks

Different combinations carry different risk profiles. Understanding the specific dangers of each pattern informs the clinical approach.

• Opioids and benzodiazepines: the most deadly combination. Both suppress the central nervous system and breathing; their combined effect on respiratory depression is more than additive. The FDA issued a black-box warning for this combination, and CDC data finds benzodiazepines present in a substantial proportion of opioid overdose deaths
• Opioids and stimulants (speedball): cocaine or methamphetamine used with heroin or fentanyl. The stimulant masks some sedative effects, creating a false sense of safety and allowing higher opioid doses than would otherwise be tolerable, dramatically raising overdose risk
• Alcohol with opioids or sedatives: all three suppress the CNS, and combinations raise respiratory depression risk significantly. Cocaethylene, produced when cocaine and alcohol combine, is more cardiotoxic than either drug alone
• Cannabis with other substances: cannabis is sometimes used to manage anxiety or insomnia alongside other substances; its interaction profile is less immediately dangerous but its effect on motivation and engagement in recovery is clinically relevant
• Nicotine: the most universally co-occurring substance in addiction populations. Addressing nicotine dependence during addiction treatment improves long-term outcomes for other substances but is often neglected
• Stimulants and benzodiazepines: used in cycles; stimulant use drives anxiety and insomnia, benzos are used to manage the comedown; each drives higher use of the other

Why polysubstance use complicates treatment planning

Polysubstance use complicates treatment in four specific ways that distinguish it from single-substance use disorder and require a more comprehensive clinical approach.

First, different withdrawal profiles require separate management. A client who uses both heroin and benzodiazepines faces withdrawal syndromes with different timelines, different severity, and different medical risks. Opioid withdrawal, though miserable, rarely carries direct mortality risk on its own. Benzodiazepine withdrawal carries a real seizure risk. Managing both simultaneously requires careful clinical coordination and often inpatient or residential level medical support before outpatient treatment can begin safely.

Second, medication-assisted treatment for one substance can interact with the management of another. Buprenorphine induction timing in a client who is also dependent on benzodiazepines requires careful coordination to avoid precipitating withdrawal from one substance while managing another. Third, co-occurring mental health conditions, which are extremely common in polysubstance use disorder, are often both a driver of use across multiple substances and a complicating factor in treatment. Fourth, each substance creates its own set of relapse triggers, conditioned cues, and craving patterns. A client in recovery from both opioids and alcohol has a larger and more complex landscape of triggers to manage.

Overdose risk and response in polysubstance use

Polysubstance use, particularly combinations involving depressants, significantly elevates overdose risk and complicates the overdose response. Naloxone reverses opioid-mediated respiratory depression but does not reverse sedation from benzodiazepines, alcohol, or other non-opioid CNS depressants. Someone who overdoses on a combination of opioids and benzodiazepines may have their opioid effect partially reversed by naloxone but remain dangerously sedated from the benzodiazepine component.

• Call 911 for any suspected overdose immediately, even if naloxone is available
• Administer naloxone if an opioid is suspected or confirmed in the combination
• Multiple naloxone doses may be needed if fentanyl is present
• Stay with the person: naloxone wears off faster than fentanyl and a person can re-enter overdose
• Place in the recovery position to prevent aspiration if breathing resumes
• Do not leave a sedated person alone even if they appear to be breathing; benzodiazepine sedation is not reversed by naloxone

How The Archangel Centers approaches polysubstance treatment

The Archangel Centers is an outpatient provider offering PHP, IOP, and standard outpatient care in New Jersey and North Carolina. We do not provide medical detox, inpatient, or residential rehab. For polysubstance clients who need medically supervised withdrawal first, especially when alcohol, benzodiazepines, or opioids are involved, we coordinate detox placement with licensed partners and then bring them into our outpatient programming once they are stable.

The defining feature of effective polysubstance treatment is integration. Each substance and any co-occurring mental health condition must be addressed together in a single coordinated plan, not in parallel programs that do not communicate. Treating heroin while ignoring alcohol dependence leaves the door open to relapse via the substance that was not addressed. The Archangel Centers builds one integrated treatment plan for each client, regardless of the number of substances or conditions involved.

Assessment uses validated instruments including the ASAM Criteria, LOCUS, PHQ-9, GAD-7, and the Columbia Suicide Severity Rating Scale. Medication-assisted treatment is available for the opioid and alcohol components of polysubstance use disorder where clinically appropriate. Dual diagnosis care is the default, not an add-on.

• Comprehensive intake assessment that names every substance and any co-occurring mental health condition
• Coordination of medically supervised withdrawal for any substance requiring it before outpatient programming begins
• Medication-assisted treatment with buprenorphine, naltrexone, or naltrexone for alcohol where appropriate
• Integrated outpatient continuum: PHP, IOP, and standard outpatient with ongoing reassessment
• CBT, DBT, contingency management, and trauma-focused therapy addressing all relevant substances and conditions
• Dual diagnosis care as the clinical standard for all clients
• Family therapy and family education to address the impact on loved ones
• Naloxone education and overdose safety planning

Relapse prevention in polysubstance recovery

Relapse prevention in polysubstance recovery is more complex than for single-substance use disorder because each substance creates its own set of conditioned cues and craving patterns. A client who used alcohol to ease anxiety and opioids to manage pain has two distinct relapse pathways, each with its own triggers, each capable of serving as a gateway to the other.

Effective relapse prevention in polysubstance treatment explicitly maps each substance's triggers, emotional precursors, and high-risk situations. It also addresses the interaction patterns, such as the way alcohol lowered inhibition and led back to opioid use, that maintain the cycle across substances. The Archangel Centers builds individualized relapse prevention plans that account for the full complexity of each client's use history.